Information Provided By:
Fly News Breaks for October 4, 2019
SGEN, REGN, NBIX, INCY, GWPH, GMAB, BIIB, ALXN
Oct 4, 2019 | 08:34 EDT
Guggenheim analysts Whitney Ijem, Etzer Darout, Yatin Suneja and Michael Schmidt offered a preview for their joint Biotech coverage ahead of the group's earnings reporting season. Biotech stocks continued their downward trend in the quarter amid negative market sentiment and the analysts think the bar for companies to raise 2019 guidance again may be a bit higher following increases in FY19 consensus estimates on the heels of strong Q2 earnings results. However, they are postively biased on the group and have confidence in FY19 guidance and estimates, the analysts said. They see Alexion (ALXN), Biogen (BIIB), Genmab (GMAB), GW Pharmaceuticals (GWPH), Incyte (INCY), Neurocrine (NBIX), Regeneron (REGN) and Seattle Genetics (SGEN) as well positioned relative to expectations, Ijem, Darout, Suneja and Schmidt tell investors.
News For ALXN;BIIB;GMAB;GWPH;INCY;NBIX;REGN;SGEN From the Last 2 Days
There are no results for your query ALXN;BIIB;GMAB;GWPH;INCY;NBIX;REGN;SGEN